Skip to Content

Morria Biopharmaceuticals Plc. Announces Publication of the Results of Its Human Pilot Study in Contact Dermatitis Patients of MRX1, a Novel First-in-Class MFAID

LONDON--(BUSINESS WIRE)--Feb 14, 2007 - Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today the publication of results from its human pilot clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX1. The results of the study are published in the upcoming edition of the International Journal of Immunopathology and Pharmacology. MRX1 was tested in a double-blind placebo controlled study on 11 contact dermatitis patients at the Hadassah University Hospital in Israel. The pilot clinical study findings show that a topical preparation of MRX1, applied twice daily for 14 days, scored 69% improvement based on conventional Physician's Assessment versus a standard 30% placebo effect generated by the moisturizing vehicle.

"These results mark an important milestone for Morria's unique proprietary technology," said Dr. Yuval Cohen, Managing Director of Morria Biopharmaceuticals Plc. "Our aim is to continue expanding in the inflammatory skin disease area as well as accelerate our parallel program in the respiratory field and in gastro-intestinal inflammation. We expect more clinical trial in these fields to commence in the near future. These programs, coupled with the industry discovery partnerships we are currently engaged in, demonstrate the potent transformative potential that our technology possesses."

Prof. Arieh Ingber, Principle Investigator of the study and the head of the Department of Dermatology at Hadassah Hospital, added, "I believe these results are very promising and may provide a much needed alternative to current topical treatments such as corticosteroids."


Contact dermatitis is an allergic condition in which patients develop skin reactions when coming into contact with certain materials/substances such as metals, latex and fabrics. The market for this condition is estimated at $600m. Contact dermatitis is a standard industry model of studying skin inflammation in humans.


Morria Biopharmaceuticals Plc is a biopharmaceutical company focusing on the development of anti-inflammatory agents termed Multi-Functional Anti-Inflammatory Drugs (MFAID). Morria is determined to use its unique technological and cost advantage to become a major player in the $50bn anti-inflammatory drug market within the next decade through the introduction of novel drugs for the treatment of a variety of chronic inflammatory conditions including skin, airway and gastro-intestinal inflammatory diseases.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information.


Morria Biopharmaceuticals Plc
Yuval Cohen, +44 (0)207 152 6341
Managing Director

Posted: February 2007